Alexion to pay $855m for Swedish biotech with Ph III candidate
Alexion Pharmaceuticals has announced plans to buy Wilson Therapeutics and its lead candidate WTX101, which has received Fast Track designation.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs